Gerber Kawasaki Wealth & Investment Management Sells 208,035 Shares of Invesco Biotechnology & Genome ETF $PBE

Gerber Kawasaki Wealth & Investment Management lowered its stake in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 81.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,137 shares of the company’s stock after selling 208,035 shares during the quarter. Gerber Kawasaki Wealth & Investment Management’s holdings in Invesco Biotechnology & Genome ETF were worth $3,224,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in PBE. Allworth Financial LP acquired a new position in Invesco Biotechnology & Genome ETF during the 2nd quarter worth approximately $54,000. Envestnet Asset Management Inc. lifted its stake in Invesco Biotechnology & Genome ETF by 7.7% in the 3rd quarter. Envestnet Asset Management Inc. now owns 19,723 shares of the company’s stock valued at $1,378,000 after purchasing an additional 1,408 shares during the last quarter. Blair William & Co. IL boosted its position in Invesco Biotechnology & Genome ETF by 150.0% in the third quarter. Blair William & Co. IL now owns 1,000 shares of the company’s stock valued at $70,000 after buying an additional 600 shares in the last quarter. Royal Bank of Canada boosted its position in Invesco Biotechnology & Genome ETF by 22.3% in the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after buying an additional 13,767 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Invesco Biotechnology & Genome ETF by 5.9% during the first quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock worth $2,389,000 after buying an additional 2,103 shares during the last quarter.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of NYSEARCA:PBE opened at $77.78 on Monday. Invesco Biotechnology & Genome ETF has a 52-week low of $54.52 and a 52-week high of $85.73. The company has a market capitalization of $249.67 million, a PE ratio of 20.44 and a beta of 0.79. The company has a fifty day moving average of $82.17 and a 200-day moving average of $77.44.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.